

1 Article type: Original article

2 Title: Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-  
3 19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an  
4 mRNA vaccine to unvaccinated patients

5 Robert Whittaker (MSc)<sup>a\*</sup>, Anja Bråthen Kristofferson (PhD)<sup>b</sup>, Beatriz Valcarcel Salamanca (PhD)<sup>b</sup>,  
6 Elina Seppälä (MD)<sup>a</sup>, Karan Golestani (MD)<sup>c</sup>, Reidar Kvåle (PhD)<sup>d, e</sup>, Sara Viksmoen Watle (MD)<sup>a</sup>, Eirik  
7 Alnes Buanes (PhD)<sup>d, f</sup>

8 Family names are underlined.

9 a) Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo,  
10 Norway.

11 b) Department of Method Development and Analytics, Norwegian Institute of Public Health,  
12 Oslo, Norway.

13 c) Department of Infection Control and Preparedness, Norwegian Institute of Public Health,  
14 Oslo, Norway.

15 d) Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen,  
16 Norway.

17 e) Department of Clinical Medicine, University of Bergen, Bergen, Norway.

18 f) Norwegian Intensive Care and Pandemic Registry, Haukeland University Hospital, Bergen,  
19 Norway.

20 \* Corresponding author: Robert Whittaker, Norwegian Institute of Public Health, Lovisenberggata 8,  
21 0456, Oslo, Norway; Phone: +47 21 07 63 93; Email: [Robert.Whittaker@fhi.no](mailto:Robert.Whittaker@fhi.no)

## 22 **Abstract**

### 23 **Objectives**

24 With most of the Norwegian population vaccinated against COVID-19, an increasing number and  
25 proportion of COVID-19 related hospitalisations are occurring among vaccinated patients. We  
26 estimated the length of stay (LoS) in hospital and an intensive care unit (ICU), and risk of admission to  
27 ICU and in-hospital death among COVID-19 patients  $\geq 18$  years who had been fully vaccinated with an  
28 mRNA vaccine, compared to unvaccinated patients.

### 29 **Methods**

30 Using national registry data, we conducted a cohort study on SARS-CoV-2 positive patients  
31 hospitalised in Norway between 1 February and 30 November 2021, with COVID-19 as the main  
32 cause of hospitalisation. We ran Cox proportional hazards models to analyse differences in our  
33 outcomes. Explanatory variables included vaccination status, age, sex, county of residence, regional  
34 health authority, date of admission, country of birth, virus variant and underlying risk factors.

### 35 **Results**

36 We included 3,203 patients, of whom 716 (22%) were fully vaccinated (at least two doses or one  
37 dose and previous SARS-CoV-2 infection). Fully vaccinated patients had a shorter overall LoS in  
38 hospital (aHR for discharge: 1.61, 95%CI: 1.24–2.08), shorter LoS without ICU (aHR: 1.27, 95%CI:  
39 1.07–1.52), and lower risk of ICU admission (aHR: 0.50, 95%CI: 0.37–0.69) compared to unvaccinated  
40 patients. We observed no difference in the LoS in ICU, nor risk of in-hospital death between fully  
41 vaccinated and unvaccinated patients.

## 42 **Conclusions**

43 Fully vaccinated patients hospitalised with COVID-19 in Norway have a shorter LoS and lower risk of  
44 ICU admission than unvaccinated patients. These findings can support patient management and  
45 ongoing capacity planning in hospitals.

46

47 Keywords: Norway; SARS-CoV-2; hospitalisation; length of stay; intensive care; mRNA vaccine;  
48 breakthrough infection

## 49 Introduction

50 COVID-19 vaccination programmes have drastically reduced the burden of COVID-19 related  
51 hospitalisations and deaths (1-5). However, the risk of breakthrough cases of severe COVID-19 after  
52 vaccination remains, particularly among groups at higher risk of severe disease (6, 7).  
53 Norway (population 5.4 million) started COVID-19 vaccination in December 2020, initially focusing on  
54 individuals  $\geq 65$  years, health care workers and individuals at increased risk of severe COVID-19 (8).  
55 The mRNA vaccines Comirnaty<sup>®</sup> (BioNTech-Pfizer, Mainz, Germany/New York, United States) and  
56 Spikevax<sup>®</sup> (mRNA-1273, Moderna, Cambridge, United States) are the two predominant vaccines  
57 administered (9). National second dose coverage among  $\geq 18$ -year-olds reached 87% by 30 November  
58 2021. Persons with specific immunosuppressive conditions were offered a third dose as part of the  
59 primary series from September (10). Booster doses have been offered to persons  $\geq 65$  years and care  
60 home residents since October, and health care workers since November 2021 (11).  
61 With high national vaccination coverage, an increasing number and proportion of COVID-19 related  
62 hospitalisations are occurring among vaccinated patients, characterised by advanced age and  
63 underlying comorbidities that increase the risk of severe COVID-19 (8, 12). It is therefore essential to  
64 understand how vaccination may affect clinical endpoints among patients who are hospitalised for  
65 COVID-19 to support patient management and capacity planning in hospitals. Published data on this  
66 are currently limited (13, 14).  
67 We linked individual-level data from national registries to estimate the length of stay (LoS) in hospital  
68 (with and without intensive care unit (ICU) stay) and ICU, and risk of ICU admission and in-hospital  
69 death among COVID-19 patients  $\geq 18$  years in Norway who had been fully vaccinated with an mRNA  
70 vaccine, compared to unvaccinated patients.

## 71 Methods

## 72 **Patient cohort**

73 We conducted a cohort study on patients  $\geq 18$  years hospitalised between 1 February and 30  
74 November 2021 after a positive SARS-CoV-2 test and who had a national identity number registered.  
75 We included patients hospitalised  $\leq 2$  days before and  $\leq 28$  days following a positive SARS-CoV-2 test,  
76 where COVID-19 was the reported main cause of hospitalisation. Cases hospitalised with other or  
77 unknown main cause were excluded. We did not restrict admissions by LoS. The Alpha variant was  
78 the predominant circulating variant at the start of the study period, before being superseded by  
79 Delta in early July (15).

## 80 **Data sources**

81 We obtained data from the Norwegian national emergency preparedness registry for COVID-19 (16).  
82 This registry contains individual-level data on all laboratory-confirmed COVID-19 cases, COVID-19  
83 related hospitalisations and ICU admissions, and COVID-19 vaccinations among Norwegian residents.  
84 Further details on the data sources and national COVID-19 vaccination coverage over time by age  
85 group and number of doses, are presented in supplementary materials A, part 1. We extracted data  
86 from the preparedness registry on 14 December 2021, ensuring a minimum of 13 days follow-up  
87 since last date of hospitalisation.

## 88 **Definition of COVID-19 vaccination status**

89 Vaccination status was defined on the date of positive test for SARS-CoV-2:

- 90 1. Unvaccinated: Not vaccinated with a COVID-19 vaccine.
- 91 2. Fully vaccinated: Positive test  $\geq 7$  days after second dose with at least the absolute minimum  
92 interval between doses depending on vaccine type (17), or  $\geq 7$  days after first dose if  
93 previously diagnosed with a SARS-CoV-2 infection  $\geq 21$  days before vaccination.

94 We excluded patients vaccinated with only one dose, those who had received a second dose <7 days  
95 before date of positive test, and patients vaccinated with a non-mRNA vaccine only. We also  
96 excluded unvaccinated patients with reported reinfections of SARS-CoV-2.

## 97 **Outcome measures**

98 Our outcomes were discharge from hospital (with and without ICU admission), admission to ICU,  
99 discharge from ICU and in-hospital death. We calculated LoS as the time between first admission and  
100 last discharge. For patients with more than one registered hospital stay, we included time between  
101 stays, if the time between two consecutive stays was <24 hours. For LoS in ICU, we included time  
102 between consecutive stays if <12 hours. Separate stays were registered if a patient was discharged  
103 and readmitted, or if a patient was transferred between wards or hospitals. Patients with unknown  
104 date of discharge from their last stay were considered to still be hospitalised. In-hospital death was  
105 registered at discharge.

## 106 **Data analysis**

107 Explanatory variables used to analyse differences in our outcomes were vaccination status, age, sex,  
108 county of residence, regional health authority, date of admission, country of birth, virus variant and  
109 underlying risk factors (Table 1).

110 Outcomes were first explored univariably in a Cox proportional hazards model and by calculating  
111 Kaplan Meier curves, with right censoring of patients still admitted to hospital. Crude log hazard  
112 ratios together with medians and interquartile ranges (IQR) for LoS were obtained. Explanatory  
113 variables with a p value <0.2 were further explored in multivariable models. Forward model selection  
114 was performed based on Akaike Information Criterion. Vaccination status was maintained in all  
115 models regardless of significance. Continuous variables (date of admission and age) were tested as  
116 linear, spline or categorically. The multivariable model was checked for the assumption of

117 proportional hazard by checking Schoenfeld residuals, and some explanatory variables were stratified  
118 to satisfy the assumption. The adjusted log hazard ratios (aHR) obtained in the multivariable models  
119 were reported. We ran models on all patients  $\geq 18$  years, as well as for the following age subgroups:  
120 18–64 years, 65–79 years and  $\geq 80$  years. Patients vaccinated with three doses were not analysed  
121 separately due to small numbers. LoS in ICU was not analysed for the age subgroups due to the small  
122 number of vaccinated patients admitted to ICU in each subgroup ( $\leq 50$ ).

123 We also conducted sensitivity analyses by changing the definition of our study population, study  
124 period or our outcome definitions to further explore if our main results were robust (supplementary  
125 materials A, part 2). The statistical analysis was performed in R version 3.6.2.

## 126 **Ethics**

127 Ethical approval for this study was granted by Regional Committees for Medical Research Ethics -  
128 South East Norway, reference number 249509. The need for informed consent was waived.

## 129 **Results**

### 130 **Description of cohort**

131 During the study period, 3,541 reported cases of COVID-19 were hospitalised with COVID-19 as the  
132 main cause of hospitalisation  $\leq 2$  days before and  $\leq 28$  days after a positive SARS-CoV-2 test. Of these,  
133 3,476 (98%) had a national identity number registered. We excluded 262 patients vaccinated with  
134 only one dose or a second dose  $< 7$  days before date of positive test, four patients vaccinated with  
135 non-mRNA vaccines, one patient with unknown vaccine type and two unvaccinated patients who  
136 were reported as having been reinfected with SARS-CoV-2. We also dropped four patients who had a  
137 reported stay in ICU outside of their hospital stay, due to assumed incomplete reporting on hospital  
138 stays. Our study cohort included the remaining 3,203 patients.

139 The median time from positive test to hospitalisation was 5 days (IQR 1–8), and 3,157 (99%) patients  
140 were admitted within 14 days of positive test. In total, 583 (18%) patients were admitted to ICU. At  
141 the end of follow-up, 75 (2.3%) patients were still hospitalised. Of the 3,128 patients who had been  
142 discharged, 188 (6.0%) died in hospital. In total, 716 (22%) patients were fully vaccinated, of whom  
143 666 (93%) had received two doses, 47 (6.6%) three doses and three (0.4%) one dose with a previous  
144 SARS-CoV-2 infection. Most patients (658, 92%) received a homologous Comirnaty regimen. A full  
145 breakdown of vaccine types and time between doses is presented in supplementary materials A, part  
146 3. The median time from last dose to diagnosis was 174 days (IQR: 126–217). Age and the frequency  
147 of certain underlying risk factors such as cancer, chronic lung disease, heart disease,  
148 immunosuppression (due to illness or treatment) and kidney disease were higher among fully  
149 vaccinated patients. Detailed characteristics of the study cohort by vaccination status are presented  
150 in Table 1. Equivalent descriptive data per age subgroup are available in supplementary materials B.

## 151 **Length of stay in hospital and intensive care, and risk of admission** 152 **to intensive care and in-hospital death by vaccination status**

153 Descriptive data and crude and adjusted hazard ratios for each outcome by age subgroup and  
154 vaccination status are presented in Tables 2 and 3, and Figure 1. Estimates from all univariable and  
155 multivariable models in the main analysis are presented in supplementary materials B and C.

156 Our multivariable models suggested that fully vaccinated patients  $\geq 18$  years had a shorter overall LoS  
157 in hospital (aHR for discharge: 1.61, 95%CI: 1.24–2.08) and shorter LoS without ICU admission (aHR:  
158 1.28, 95%CI: 1.07–1.52) compared to unvaccinated patients. Considering exponential distribution of  
159 the survival data, an aHR for discharge of 1.61 translates into an average 38% shorter LoS ( $1 - 1/1.61$ )  
160 (18). Fully vaccinated patients also had a 50% lower risk of ICU admission (aHR: 0.50, 95%CI: 0.37–  
161 0.69) compared to unvaccinated patients. We did not observe a difference in the LoS in ICU (aHR:



162 1.03, 95%CI: 0.80–1.31), or risk of in-hospital death (aHR: 1.00, 95%CI: 0.54–1.85) between  
163 vaccinated and unvaccinated patients (Figure 1, Table 3).

164 By age subgroup, fully vaccinated patients 18–64 years had an average 48% shorter overall LoS (aHR  
165 for discharge: 1.91, 95%CI: 1.37–2.66), 32% shorter LoS without ICU admission (aHR: 1.46, 95%CI:  
166 1.11–1.91) and 47% lower risk of ICU admission (aHR: 0.53, 95%CI: 0.32–0.88), compared to  
167 unvaccinated individuals. Fully vaccinated patients 65–79 years had an average 22% shorter overall  
168 LoS (aHR for discharge: 1.29, 95%CI: 1.10–1.52) and 36% lower risk of ICU admission (aHR: 0.64,  
169 95%CI: 0.46–0.89) compared to unvaccinated patients. There was no difference in the adjusted risk  
170 of in-hospital death between vaccinated and unvaccinated patients in any age subgroup. We did not  
171 observe a difference between vaccinated and unvaccinated patients  $\geq 80$  years in adjusted estimates  
172 for any outcome.

173 Results were generally robust in our sensitivity analyses, including when we analysed a period after  
174 which all persons in different age subgroups had been offered two vaccine doses, and when we  
175 excluded patients who had received three doses (supplementary materials A, part 2).

## 176 Discussion

177 In this national register-based study, we have analysed individual-level data on 3,203 hospitalised  
178 COVID-19 patients, during a period when the majority were offered mRNA vaccines in a two-dose  
179 schedule. In line with other reports (7, 13, 14, 19), vaccinated patients were generally older and had  
180 a higher prevalence of underlying risk factors than unvaccinated patients. We find that fully  
181 vaccinated patients had a shorter LoS in hospital (both with and without ICU admission) and lower  
182 risk of ICU admission compared to unvaccinated patients. There was no difference in the LoS in ICU,  
183 or risk of in-hospital death.

184 Our results suggest that once hospitalised the risk of death among fully vaccinated and unvaccinated  
185 patients in Norway is similar. However, for survivors the disease trajectory is milder in fully

186 vaccinated patients, with reduced need for hospital care and organ support. For patients not  
187 admitted to ICU, the observed reduction in LoS may have been attenuated by vaccinated patients,  
188 who may have ended up in ICU if unvaccinated, now instead spending more time in regular wards.  
189 The greatest relative reductions in LoS and risk of ICU admission were observed among patients 18–  
190 64 years. For all outcomes, we observed no difference between vaccinated and unvaccinated  
191 patients  $\geq 80$  years. Vaccine effectiveness against hospitalisation has been reported to be lower  
192 among older age groups in Norway (20). This age group is also generally less frequently admitted to  
193 ICU, and it could be that treatment limitations confound vaccine effects in the elderly. However, the  
194 small number of unvaccinated patients  $\geq 80$  years should be considered. Our results also highlight  
195 that factors other than vaccination also continue to influence patient outcomes. A longer LoS and/or  
196 increased risk of ICU admission or death were associated with advanced age, male sex and certain  
197 risk factors such as immunosuppression, kidney disease, obesity and diabetes, as reported by others  
198 (21-24).

199 These findings build on previous evidence of high vaccine effectiveness against severe disease (1-5,  
200 20) and have important implications for patient management and ongoing capacity planning in  
201 hospitals. A study including 142 patients fully vaccinated with an mRNA vaccine from 21 sites across  
202 the United States also reported a shorter LoS, lower risk of death or invasive mechanical ventilation  
203 and a lower level of clinical disease severity among vaccinated patients (13). In contrast, a study from  
204 Michigan, United States did not find lower risk of ICU admission, mechanical ventilation or death  
205 when comparing 129 fully vaccinated patients (vaccinated with Comirnaty, Spikevax or Janssen) to  
206 unvaccinated patients (14). Differences in the study cohorts, setting and design need to be  
207 considered. In this study we compare fully vaccinated and unvaccinated patients, however  
208 vaccination programmes are continuing to evolve and future analyses will be necessary to explore  
209 how parameters such as vaccine type, number of doses, time since vaccination and dose intervals  
210 affect patient outcomes between groups of vaccinated patients. While studies have suggested  
211 sustained high effectiveness of mRNA vaccines against hospitalisation at least six months following

212 vaccination (25, 26), the duration of protection following the original two-dose schedules for mRNA  
213 vaccines and the effects of booster doses (27, 28) require ongoing research.

214 A strength of our study is that all data sources had national coverage. We also had a notably larger  
215 cohort of fully vaccinated patients compared to previous studies (13, 14). Also, hospitals in Norway  
216 functioned within capacity during the study period, and criteria for hospitalisation and isolation for  
217 COVID-19 patients were consistent and not related to vaccination status. Although we did not have  
218 access to treatment data, there were no major changes in treatment guidelines for COVID-19  
219 patients in hospital or ICU in Norway during the study period. We also had minimal censoring of the  
220 study cohort, with 2.3% of patients still admitted to hospital at the end of follow-up.

221 Our study also has limitations. While we have controlled for several important confounders, the  
222 observational nature has the potential for residual confounding. Our fully vaccinated cohort is also  
223 predominantly representative of patients who received a homologous Comirnaty regimen. Another  
224 limitation is that some of our reported underlying risk factors do not distinguish potential differences  
225 within groups, for example whether risk factors are well-regulated or treated. Also, 40% of patients  
226 had unknown body mass index. Our model may therefore not fully adjust for certain underlying risk  
227 factors. Further, our study cohort does not include care home residents who in Norway are generally  
228 recommended to receive treatment for severe COVID-19 in their care home, not in hospital. Finally,  
229 previous natural infection has been associated with a high level of protection against SARS-CoV-2  
230 reinfection (29, 30). While we dropped two reported reinfections, we cannot rule out that there  
231 were other previously undiagnosed SARS-CoV-2 infections in our unvaccinated cohort. If present, this  
232 may cause us to underestimate the effect of vaccination.

233 Our study suggests that mRNA vaccinated patients hospitalised with COVID-19 in Norway have a  
234 shorter LoS and lower risk of ICU admission than unvaccinated patients. These findings can support  
235 patient management and ongoing capacity planning in hospitals and underline the importance of  
236 vaccination programmes against COVID-19.

## 237 **Transparency declaration**

## 238 **Authors' contributions**

239 RW, ABK, BVS, ES, RK and EAB conceived the idea for the study. RW drafted the study protocol and  
240 coordinated the study. RK and EAB contributed directly to the acquisition of data. RW and ABK  
241 contributed to data cleaning, validation and preparation. RW and ABK led the data analysis. All co-  
242 authors contributed to the interpretation of the results. RW and ABK drafted the manuscript. All co-  
243 authors contributed to the revision of the manuscript and approved the final version for submission.

## 244 **Conflict of interest**

245 The authors declare that they have no competing interests.

## 246 **Funding**

247 The authors received no specific funding for this work.

## 248 **Acknowledgements**

249 First and foremost, we wish to thank all those who have helped establish, coordinate and report data  
250 to the national emergency preparedness registry at the Norwegian Institute of Public Health (NIPH)  
251 throughout the pandemic. We also highly acknowledge the efforts of staff at hospitals around  
252 Norway to ensure the reporting of timely and complete data to the Norwegian Intensive Care and  
253 Pandemic Registry, as well as colleagues at the register itself. We would like to specifically thank  
254 Trude Marie Lyngstad, Jostein Starrfelt, Håkon Bøås and Lamprini Veneti at the NIPH for their  
255 assistance in cleaning the data from different registries, and additionally Trude Marie Lyngstad for  
256 assistance in the production of Figure S1.

## 257 **Access to data**

258 The dataset analysed in the study contains individual-level linked data from various central health  
259 registries, national clinical registries and other national administrative registries in Norway. The  
260 researchers had access to the data through the national emergency preparedness registry for COVID-  
261 19 (Beredt C19), housed at the Norwegian Institute of Public Health (NIPH). In Beredt C19, only fully  
262 anonymised data (i.e. data that are neither directly nor potentially indirectly identifiable) are  
263 permitted to be shared publicly. Legal restrictions therefore prevent the researchers from publicly  
264 sharing the dataset used in the study that would enable others to replicate the study findings.  
265 However, external researchers are freely able to request access to linked data from the same  
266 registries from outside the structure of Beredt C19, as per normal procedure for conducting health  
267 research on registry data in Norway. Further information on Beredt C19, including contact  
268 information for the Beredt C19 project manager, and information on access to data from each  
269 individual data source, is available at [https://www.fhi.no/en/id/infectious-](https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/)  
270 [diseases/coronavirus/emergency-preparedness-register-for-covid-19/](https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/).

## 271 **References**

- 272 1. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness  
273 of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021;385(7):585-94.
- 274 2. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-  
275 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national  
276 prospective cohort study. *Lancet*. 2021;397(10285):1646-57.
- 277 3. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of  
278 SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. *Clin Infect*  
279 *Dis*. 2021.
- 280 4. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness  
281 of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and  
282 deaths following a nationwide vaccination campaign in Israel: an observational study using national  
283 surveillance data. *Lancet*. 2021;397(10287):1819-29.
- 284 5. Glatman-Freedman A, Bromberg M, Dichtiar R, Hershkovitz Y, Keinan-Boker L. The BNT162b2  
285 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A  
286 nation-wide retrospective longitudinal multiple cohort analysis using individualised data.  
287 *EBioMedicine*. 2021;72:103574.
- 288 6. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk  
289 prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination:  
290 national prospective cohort study. *BMJ*. 2021;374:n2244.
- 291 7. Brosh-Nissimov T, Orenbuch-Harroch E, Chowars M, Elbaz M, Neshet L, Stein M, et al.  
292 BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-  
293 19 patients in Israel. *Clin Microbiol Infect*. 2021.

- 294 8. Norwegian Institute of Public Health. Who will get the coronavirus vaccine? 2021 [cited 2021  
295 Dec 15]. Available from: [https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)  
296 [programme/who-will-get-coronavirus-vaccine-first/](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)
- 297 9. Norwegian Institute of Public Health. Coronavirus vaccine - information for the public. 2021  
298 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)  
299 [programme/who-will-get-coronavirus-vaccine-first/](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)
- 300 10. Norwegian Institute of Public Health. Personer med nedsatt immunforsvar anbefales en  
301 tredje vaksinedose. Oslo: Norwegian Institute of Public Health. 2021 [cited 2021 Dec 15]. Available  
302 from: [https://www.fhi.no/nyheter/2021/personer-med-nedsatt-immunforsvar-anbefales-en-tredje-](https://www.fhi.no/nyheter/2021/personer-med-nedsatt-immunforsvar-anbefales-en-tredje-vaksinedose/)  
303 [vaksinedose/](https://www.fhi.no/nyheter/2021/personer-med-nedsatt-immunforsvar-anbefales-en-tredje-vaksinedose/)
- 304 11. Norwegian Institute of Public Health. Flere anbefales tre doser med koronavaksine. 2021  
305 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/nyheter/2021/flere-anbefales-tre-doser-](https://www.fhi.no/nyheter/2021/flere-anbefales-tre-doser-med-koronavaksine/)  
306 [med-koronavaksine/](https://www.fhi.no/nyheter/2021/flere-anbefales-tre-doser-med-koronavaksine/)
- 307 12. Norwegian Institute of Public Health. Ukerapporter om koronavirus og covid-19. Oslo:  
308 Norwegian Institute of Public Health. 2021 [cited 2021 Dec 15]. Available from:  
309 <https://www.fhi.no/publ/2020/koronavirus-ukerapporter/>
- 310 13. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghamande S, et al.  
311 Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA.  
312 2021. doi: 10.1001/jama.2021.19499.
- 313 14. Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination reduces need  
314 for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. Lancet Reg  
315 Health Am. 2021:100065.

- 316 15. Veneti L, Valcarcel Salamanca B, Seppälä E, Starrfelt J, Storm ML, Bragstad K, et al. No  
317 difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and  
318 Alpha variant in Norway. *IJID*. 2021. doi: 10.1016/j.ijid.2021.12.321
- 319 16. Norwegian Institute of Public Health. Emergency preparedness register for COVID-19 (Beredt  
320 C19). 2021 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/en/id/infectious-  
321 diseases/coronavirus/emergency-preparedness-register-for-covid-19/](https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/)
- 322 17. Norwegian Institute of Public Health. Vanlige problemstillinger om koronasertifikat. 2021  
323 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/om/koronasertifikat/til-helsepersonell-  
324 vanlige-problemstillinger-om-koronasertifikat/](https://www.fhi.no/om/koronasertifikat/til-helsepersonell-vanlige-problemstillinger-om-koronasertifikat/)
- 325 18. Barraclough H, Simms L, Govindan R. Biostatistics primer: what a clinician ought to know:  
326 hazard ratios. *J Thorac Oncol*. 2011;6(6):978-82.
- 327 19. Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, et al.  
328 COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57  
329 million people in Scotland (EAVE II): a prospective cohort study. *Lancet Respir Med*. 2021.
- 330 20. Starrfelt J, Buanes EA, Juvet LK, Lyngstad TM, Rø GOI, Veneti L. Age and product dependent  
331 vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a  
332 national cohort study, January – September 2021. *Medrxiv*. 2021 [cited 2021 Dec 15]. Available from:  
333 <https://www.medrxiv.org/content/10.1101/2021.11.12.21266222v1>
- 334 21. Suarez-Garcia I, Perales-Fraile I, Gonzalez-Garcia A, Munoz-Blanco A, Manzano L, Fabregate  
335 M, et al. In-hospital death among immunosuppressed patients with COVID-19: Analysis from a  
336 national cohort in Spain. *PLoS One*. 2021;16(8):e0255524.
- 337 22. Boelle PY, Delory T, Maynadier X, Janssen C, Piarroux R, Pichenot M, et al. Trajectories of  
338 Hospitalization in COVID-19 Patients: An Observational Study in France. *J Clin Med*. 2020;9(10).



- 339 23. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated  
340 with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New  
341 York City: prospective cohort study. *BMJ*. 2020;369:m1966.
- 342 24. Sjögren L, Stenberg E, Thuccani M, Martikainen J, Rylander C, Wallenius V, et al. Impact of  
343 obesity on intensive care outcomes in patients with COVID-19 in Sweden-A cohort study. *PLoS One*.  
344 2021;16(10):e0257891.
- 345 25. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-  
346 1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19  
347 disease in Qatar. *Nat Med*. 2021;27(9):1614-21.
- 348 26. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of  
349 mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a  
350 retrospective cohort study. *Lancet*. 2021;398(10309):1407-16.
- 351 27. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.  
352 Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med*. 2021.
- 353 28. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe  
354 outcomes in Israel: an observational study. *Lancet*. 2021. doi: 10.1016/S0140-6736(21)02249-2.
- 355 29. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in  
356 health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection  
357 (SIREN): a prospective, multicentre, cohort study. *Lancet*. 2021;397(10286):1725-35.
- 358 30. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection  
359 against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a  
360 population-level observational study. *Lancet*. 2021;397(10280):1204-12.

## 361 Tables and figures

362 *Table 1. Characteristics of SARS-CoV-2 positive patients aged ≥18 years hospitalised with COVID-19 as*  
 363 *the main cause of hospitalisation, by vaccination status, Norway, 1 February – 30 November 2021*

Characteristics		Vaccination status	
		Unvaccinated (n=2487)	Fully vaccinated (n=716)
Sex	Male	1472 (59.2%)	414 (57.8%)
	Female	1015 (40.8%)	302 (42.2%)
		<b>p = 0.531</b>	
Age group	18-29 years	157 (6.3%)	6 (0.8%)
	30-44 years	640 (25.7%)	32 (4.5%)
	45-54 years	645 (25.9%)	49 (6.8%)
	55-64 years	510 (20.5%)	93 (13.0%)
	65-79 years	453 (18.2%)	260 (36.3%)
	≥80 years	82 (3.3%)	276 (38.5%)
		<b>p &lt; 0.001</b>	
Median age	In years (IQR)	51 (41–62)	76 (64–83)
			<b>p &lt; 0.001</b>
Born in Norway	Yes, with at least one parent born in Norway	1037 (41.7%)	546 (76.3%)
	Yes, two parents born outside of Norway	62 (2.5%)	4 (0.6%)
	No	1311 (52.7%)	113 (15.8%)
	Unknown	77 (3.1%)	53 (7.4%)

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

			p < 0.001
Underlying risk factors	Asthma	272 (10.9%)	74 (10.3%)
	Cancer <sup>a</sup>	63 (2.5%)	93 (13.0%)
	Chronic lung disease, excluding asthma	134 (5.4%)	143 (20.0%)
	Chronic neurological or neuromuscular disease	88 (3.5%)	60 (8.4%)
	Diabetes (type 1 and 2)	352 (14.2%)	166 (23.2%)
	Heart disease, including hypertension	659 (26.5%)	433 (60.5%)
	Immunosuppression, including HIV and immunosuppressive treatment <sup>b</sup>	63 (2.5%)	96 (13.4%)
	Kidney disease, including kidney failure	73 (2.9%)	126 (17.6%)
	Liver disease, including liver failure	24 (1.0%)	13 (1.8%)
	BMI ≥30 <sup>c</sup>	585 (23.5%)	104 (14.5%)
	Pregnant	66 (2.7%)	1 (0.1%)
	Current smoker	104 (4.2%)	25 (3.5%)
Virus variant	Alpha	1038 (41.7%)	12 (1.7%)
	Beta	22 (0.9%)	1 (0.1%)
	Delta	375 (15.1%)	341 (47.6%)
	Non-VOC	70 (2.8%)	3 (0.4%)
	Uncategorised <sup>d</sup>	58 (2.3%)	2 (0.3%)
	Unknown	924 (37.2%)	357 (49.9%)
			p < 0.001

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Month of admission	February	197 (7.9%)	0 (0.0%)
	March	733 (29.5%)	6 (0.8%)
	April	560 (22.5%)	9 (1.3%)
	May	201 (8.1%)	3 (0.4%)
	June	97 (3.9%)	4 (0.6%)
	July	48 (1.9%)	11 (1.5%)
	August	113 (4.5%)	44 (6.1%)
	September	161 (6.5%)	105 (14.6%)
	October	121 (4.9%)	167 (23.3%)
	November	256 (10.3%)	367 (51.3%)
Regional health authority	South-East	146 (5.9%)	86 (12.0%)
	West	142 (5.7%)	90 (12.6%)
	Mid	1919 (77.2%)	457 (63.8%)
	North	280 (11.3%)	83 (11.6%)
			p < 0.001
Admission to ICU	No	2007 (80.7%)	613 (85.6%)
	Yes	480 (19.3%)	103 (14.4%)
			p = 0.003
Death <sup>e</sup>	Died in ICU	67 (2.7%)	30 (4.4%)
	Died in hospital, not in ICU	35 (1.4%)	56 (8.2%)
	Alive at discharge	2346 (95.8%)	594 (87.4%)
			p < 0.001

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Number of patients	In ICU	18 (0.7%)	15 (2.1%)
still in hospital at end			
of follow-up (13	In hospital, not in ICU	21 (0.8%)	21 (2.9%)
December 2021)	Discharged from hospital	2448 (98.4%)	680 (95.0%)
			p < 0.001

364 IQR: interquartile range; VOC: Variant of concern; ICU: Intensive care unit; BMI: Body mass index. P values compared to unvaccinated

365 calculated using chi-squared tests or Wilcoxon rank sum tests as appropriate. P values for underlying risk factors based on proportion

366 having any one of the listed risk factors. Equivalent descriptive data per age subgroup are available in supplementary materials B.

367 <sup>a</sup> Refers to cancer patients undergoing treatment or with regular controls (>1 per year).

368 <sup>b</sup> Includes ongoing use of steroids in doses equivalent to at least 5mg Prednisolone daily.

369 <sup>c</sup> In our dataset, 1,270 patients (40%) had unknown information on height and weight, and thus unknown data on BMI. Of these 1,270, 962

370 were unvaccinated (39% of all unvaccinated) and 308 fully vaccinated (43%). In our models, BMI was therefore included as a three-level


371 categorical variable, yes, no and unknown.

372 <sup>d</sup> Cases for which VOC and non-VOC could not clearly be distinguished based on the available information. This does not potentially include

373 cases of the Omicron VOC, which was not detected in any patients in our study cohort.

374 <sup>e</sup> Excludes patients still in hospital at end of follow-up.

375 *Figure 1. Adjusted hazard ratios for discharge from hospital with and without stay in intensive care,*  
376 *intensive care admission, discharge from intensive care, and in-hospital death from a Cox*  
377 *proportional hazards model, SARS-CoV-2 positive patients aged ≥18 years hospitalised with COVID-19*  
378 *as the main cause of hospitalisation, by age, Norway, 1 February – 30 November 2021*



379

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

380 ICU: Intensive care unit. The reference group with a hazard ratio = 1 is patients who are male, aged 56 years (median age in  
381 dataset) without underlying risk factors and unvaccinated. Hazard ratios were calculated using a Cox proportional hazards model. The  
382 variables shown in each panel are those significantly associated with each outcome in multivariable models, which were not stratified on  
383 (see supplementary materials C). Akaike Information Criterion was used for determining whether age was included linearly or with a spline.

384

385 *Table 2. Number of patients, median number of days from admission to discharge from hospital or ICU, admissions to ICU and deaths in hospital, SARS-CoV-2*  
 386 *positive patients aged ≥18 years hospitalised with COVID-19 as the main cause of hospitalisation, by vaccination status and age group, Norway, 1 February –*  
 387 *30 November 2021*

Age group	Number of patients	Median number of days from admission to discharge from hospital (IQR) <sup>a</sup>	Median number of days from admission to discharge, patients not admitted to ICU (IQR) <sup>a</sup>	Number of patients admitted to ICU (%)	Median number of days from admission to discharge from ICU (IQR) <sup>a, b</sup>	Number of deaths in hospital (%) <sup>c</sup>
<b>Unvaccinated</b>						
18–64 years	1952	4.8 (2.5–8.7)	3.9 (2.0–6.5)	343 (18%)	-	38 (2.0%)
65–79 years	453	7.1 (3.8–14.2)	5.0 (3.0–8.7)	131 (29%)	-	47 (11%)
≥80 years	82	5.6 (2.9–8.0)	5.4 (2.9–7.1)	6 (7.3%)	-	17 (21%)
≥18 years	2487	5.0 (2.7–9.6)	4.0 (2.1–6.8)	480 (19%)	9.9 (5.3–18.0)	102 (4.2%)
<b>Fully vaccinated</b>						
18–64 years	180	4.1 (2.0–10.6)	3.4 (1.6–6.5)	35 (19%)	-	9 (5.4%)
65–79 years	260	7.0 (3.3–12.4)	5.9 (2.8–9.2)	50 (19%)	-	33 (14%)
≥80 years	276	4.7 (2.2–9.1)	4.1 (2.1–8.1)	18 (6.5%)	-	61 (16%)
≥18 years	716	5.2 (2.6–10.5)	4.2 (2.1–8.1)	103 (14%)	9.9 (4.1–17.7)	86 (13%)

388

389 ICU: Intensive care unit; IQR: Interquartile range.

390 <sup>a</sup> Estimates from univariable Cox regression, see supplementary materials B.

391 <sup>b</sup> Median number of days from admission to discharge from ICU not presented for age subgroups due to the small number of fully vaccinated patients admitted to ICU in each age subgroup (≤50).

392 <sup>c</sup> Proportions calculated excluding those still admitted at the end of the study period. 18–64 years: 25 unvaccinated, 12 fully vaccinated; 65–79 years: 13 unvaccinated, 17 fully vaccinated; ≥80 years: 1 unvaccinated, 7  
 393 fully vaccinated.



394 *Table 3. Crude and adjusted hazard ratios for discharge from hospital with and without stay in intensive care, intensive care admission, discharge from*  
 395 *intensive care, and in-hospital death from a Cox proportional hazards model, SARS-CoV-2 positive patients aged ≥18 years hospitalised with COVID-19 as the*  
 396 *main cause of hospitalisation, by age group, Norway, 1 February – 30 November 2021*

Age group	Discharge from hospital		Discharge from hospital, patients not admitted to ICU		ICU admission		Discharge from ICU		Death in hospital	
	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted <sup>a</sup> hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted <sup>a</sup> hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted <sup>a</sup> hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI) <sup>b</sup>	Adjusted <sup>a,b</sup> hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted <sup>a</sup> hazard ratio compared to unvaccinated (95%CI)
18–64 years	0.913 (0.779–1.069)	<b>1.909 (1.372–2.658)</b>	0.962 (0.811–1.142)	<b>1.455 (1.106–1.914)</b>	1.137 (0.803–1.610)	<b>0.530 (0.319–0.882)</b>	-	-	<b>2.177 (1.050–4.516)</b>	1.351 (0.636–2.871)
65–79 years	<b>1.173 (1.001–1.375)</b>	<b>1.287 (1.092–1.517)</b>	0.866 (0.725–1.034)	1.218 (0.939–1.580)	<b>0.627 (0.453–0.869)</b>	<b>0.639 (0.461–0.886)</b>	-	-	<b>1.687 (1.074–2.651)</b>	1.427 (0.892–2.284)
≥80 years	1.117 (0.869–1.434)	1.080 (0.839–1.389)	1.043 (0.806–1.349)	0.996 (0.769–1.290)	0.953 (0.378–2.403)	0.910 (0.361–2.295)	-	-	0.829 (0.473–1.453)	0.765 (0.436–1.340)
≥18 years	0.981 (0.901–1.068)	<b>1.607 (1.243–2.077)</b>	<b>0.785 (0.716–0.861)</b>	<b>1.272 (1.068–1.516)</b>	<b>0.689 (0.556–0.852)</b>	<b>0.503 (0.368–0.689)</b>	1.027 (0.817–1.292)	1.025 (0.803–1.308)	<b>3.229 (2.417–4.315)</b>	0.995 (0.536–1.847)

397 ICU: Intensive care unit; 95%CI: 95% confidence interval. Bold text = statistically significant results.

398 <sup>a</sup> Adjusted for age, sex, county of residence, regional health authority, date of admission, country of birth, virus variant and underlying risk factors (Table 1). The variables included in the final multivariable models  
 399 were obtained by forward model selection based on Akaike Information Criterion (see supplementary materials C).

400 <sup>b</sup> Not analysed for age subgroups due to the small number of fully vaccinated patients admitted to ICU in each age subgroup (≤50).